Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume -, Issue -, Pages 1-7
Publisher
Informa UK Limited
Online
2019-05-29
DOI
10.1080/14712598.2019.1622678
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study
- (2018) J Reek et al. ACTA DERMATO-VENEREOLOGICA
- Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
- (2018) A. Egeberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”
- (2018) Matteo Megna et al. CLINICAL RHEUMATOLOGY
- Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies
- (2018) Andreas Körber et al. DRUGS & AGING
- Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future
- (2018) Annunziata Raimondo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation
- (2018) Marco Galluzzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents
- (2018) Shivani B. Kaushik et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections
- (2018) Shivani B. Kaushik et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study
- (2018) Jorge R. Georgakopoulos et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
- (2018) R. Bissonnette et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Real-life effectiveness of biological drugs on psoriatic difficult-to-treat body regions: scalp, palmoplantar area and lower limbs
- (2018) M. Megna et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain
- (2018) Jaime Notario et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks
- (2018) Esther von Stebut et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
- (2017) Alice Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
- (2017) Jerry Bagel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis
- (2017) P. Gisondi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis
- (2016) Mohn’d AbuHilal et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks
- (2016) Yuan Yu Michael Huang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases
- (2016) Agnieszka Wasilewska et al. Postepy Dermatologii i Alergologii
- Secukinumab: First Global Approval
- (2015) Mark Sanford et al. DRUGS
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
- (2014) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial
- (2014) C. Paul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Psoriasis: rationale for targeting interleukin-17
- (2012) G. Girolomoni et al. BRITISH JOURNAL OF DERMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started